RT Journal Article
SR Electronic
T1 Prognostic impact of histology and treatment modalities in malignant mesothelioma
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP P3079
VO 42
IS Suppl 57
A1 Torsten Blum
A1 Jens Kollmeier
A1 Sergej Griff
A1 Timo Weiss
A1 Wim Ammenwerth
A1 Sandra Delis
A1 Wiebke Nehls
A1 Tarek Sabha
A1 Sebastian Thiel
A1 Nicolas Schönfeld
A1 Torsten T. Bauer
YR 2013
UL http://erj.ersjournals.com/content/42/Suppl_57/P3079.abstract
AB Introduction: Malignant mesothelioma is a rare and heterogenous malignancy concerning histology and the variety of approaches to its management.Aims: In times of individualized treatments for most tumour entities, this mono-centric study evaluated a retrospective cohort in order to subdivide the disease into prognostic subgroups.Methods: All patients with a malignant mesothelioma between January 2004 and December 2011 were prospectively recorded within our tumour registry and retrospectively evaluated with regard to histology, stage, treatment modalities (surgical resection [RES]: pleurectomy/decortication, extrapleural pneumonectomy; chemotherapy [CTX]; radiotherapy [RTX]) and survival.Results: A total of 170 patients were identified: 127 men (74.7%) and 43 women (25.3%). Mean age was 68.7 yrs. Histological subtyping revealed: epithelial 78.8%, sarcomatoid 8.2% and biphasic 12.9%. Treatment consisted of: RES 96 pts. (56.5%), CTX 128 pts. (75.3%), RTX 26 pts. (15.3%), including multimodal approaches. Best supportive care only was applied in 21 pts. (12.4%). Median overall survival (OS) for all pts. was 16.1 months (95% CI 14.3-18.0 months). OS was positively correlated with certain predictors including epithelial subtype and RES.Conclusion: This study confirms histologically driven survival differences in mesothelioma reported before. The favourable median OS of our cohort might be influenced by the high rate of RES.